FR24C1005I1 - Agent antitumoral et promoteur de l'effet antitumoral - Google Patents

Agent antitumoral et promoteur de l'effet antitumoral

Info

Publication number
FR24C1005I1
FR24C1005I1 FR24C1005C FR24C1005C FR24C1005I1 FR 24C1005 I1 FR24C1005 I1 FR 24C1005I1 FR 24C1005 C FR24C1005 C FR 24C1005C FR 24C1005 C FR24C1005 C FR 24C1005C FR 24C1005 I1 FR24C1005 I1 FR 24C1005I1
Authority
FR
France
Prior art keywords
antitumoral
promoter
effect
agent
antitumoral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1005C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of FR24C1005I1 publication Critical patent/FR24C1005I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Endocrinology (AREA)
FR24C1005C 2013-09-06 2024-01-24 Agent antitumoral et promoteur de l'effet antitumoral Active FR24C1005I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013184684 2013-09-06
PCT/JP2014/073436 WO2015034032A1 (fr) 2013-09-06 2014-09-05 Agent antitumoral et promoteur de l'effet antitumoral

Publications (1)

Publication Number Publication Date
FR24C1005I1 true FR24C1005I1 (fr) 2024-04-19

Family

ID=52628493

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1005C Active FR24C1005I1 (fr) 2013-09-06 2024-01-24 Agent antitumoral et promoteur de l'effet antitumoral

Country Status (23)

Country Link
US (1) US9943537B2 (fr)
EP (2) EP4201424A1 (fr)
JP (2) JP6425653B2 (fr)
KR (1) KR101993963B1 (fr)
AU (1) AU2014316030C1 (fr)
CY (1) CY1126037T1 (fr)
DK (1) DK3042669T3 (fr)
ES (1) ES2946472T3 (fr)
FI (2) FI3042669T3 (fr)
FR (1) FR24C1005I1 (fr)
HR (1) HRP20230523T1 (fr)
HU (2) HUE062034T2 (fr)
LT (1) LT3042669T (fr)
NO (1) NO2024005I1 (fr)
PL (1) PL3042669T3 (fr)
PT (1) PT3042669T (fr)
RS (1) RS64243B1 (fr)
RU (1) RU2682161C2 (fr)
SI (1) SI3042669T1 (fr)
TW (1) TWI641385B (fr)
UA (1) UA121538C2 (fr)
WO (1) WO2015034032A1 (fr)
ZA (1) ZA201602258B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3042669T3 (pl) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
WO2017119484A1 (fr) 2016-01-08 2017-07-13 大鵬薬品工業株式会社 Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
JP2019511547A (ja) * 2016-04-13 2019-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ
EP3646887A4 (fr) * 2017-06-30 2021-03-24 Korea Advanced Institute of Science and Technology Conjugué de protéine de vegf-grab et de médicament, et son utilisation
KR20220154986A (ko) 2021-05-14 2022-11-22 윤상은 휴대용 마스크끈 절단기
AR127893A1 (es) * 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr
AU2023208566A1 (en) 2022-01-21 2024-07-11 Chugai Seiyaku Kabushiki Kaisha Medicine for treating or preventing cancer
WO2024177036A1 (fr) * 2023-02-20 2024-08-29 大鵬薬品工業株式会社 Préparation combinée de ftd-tpi, antagoniste de la voie pd-1 et utilisation combinée d'un antagoniste de la voie du vegf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69629156T2 (de) 1995-03-29 2004-05-06 Taiho Pharmaceutical Co. Ltd. Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
SI1849470T2 (sl) 2005-01-26 2024-05-31 Taiho Pharmaceutical Co., Ltd. Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
PT2979701T (pt) 2013-03-27 2020-10-20 Taiho Pharmaceutical Co Ltd Agente antitumoral que inclui cloridrato de irinotecano hidratado em dose baixa
JP6002835B2 (ja) * 2013-03-27 2016-10-05 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
PL3042669T3 (pl) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy

Also Published As

Publication number Publication date
ZA201602258B (en) 2017-09-27
EP4201424A1 (fr) 2023-06-28
AU2014316030C1 (en) 2024-08-15
RU2016112421A3 (fr) 2018-06-20
JP2018076369A (ja) 2018-05-17
ES2946472T3 (es) 2023-07-19
PT3042669T (pt) 2023-06-15
JPWO2015034032A1 (ja) 2017-03-02
EP3042669B1 (fr) 2023-03-08
FI3042669T3 (fi) 2023-05-25
DK3042669T3 (da) 2023-06-12
US20160193241A1 (en) 2016-07-07
JP6425653B2 (ja) 2018-11-21
KR101993963B1 (ko) 2019-06-27
TW201536319A (zh) 2015-10-01
RU2682161C2 (ru) 2019-03-15
HUS2400001I1 (hu) 2024-02-28
LT3042669T (lt) 2023-06-26
NO2024005I1 (no) 2024-01-25
HUE062034T2 (hu) 2023-09-28
CY1126037T1 (el) 2023-11-15
US9943537B2 (en) 2018-04-17
UA121538C2 (uk) 2020-06-25
EP3042669A1 (fr) 2016-07-13
FIC20240002I1 (fi) 2024-01-25
HRP20230523T1 (hr) 2023-08-04
WO2015034032A1 (fr) 2015-03-12
EP3042669A4 (fr) 2017-04-12
KR20160050026A (ko) 2016-05-10
AU2014316030A1 (en) 2016-04-28
SI3042669T1 (sl) 2023-07-31
TWI641385B (zh) 2018-11-21
AU2014316030B2 (en) 2019-02-28
RU2016112421A (ru) 2017-10-11
PL3042669T3 (pl) 2023-06-26
JP6557744B2 (ja) 2019-08-07
RS64243B1 (sr) 2023-06-30

Similar Documents

Publication Publication Date Title
FR24C1005I1 (fr) Agent antitumoral et promoteur de l'effet antitumoral
HK1226301A1 (zh) 修飾的治療劑及其組合物
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
IL265876A (en) Preparations that include 15-ohepa and methods of using them
IL240221A0 (en) Benzomorphan analogs and their use
ZA201500698B (en) Hydroxamate substituted azaindoline-cyanine dyes and bioconjugates of the same
EP2970184A4 (fr) Composés et leurs utilisations pour la modulation d'hémoglobine
HK1217896A1 (zh) 用於治療廣泛性發展障礙的複合物及方法
IL240248A0 (en) Met-binding substances and their uses
EP3679909C0 (fr) Masque oculaire pour l'amélioration ou la prévention de la sécheresse oculaire et de conditions similaires
HK1223551A1 (zh) 種新穎的 免疫溶劑：結構和動作
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2976091C0 (fr) Composition à action antioxydante et utilisation de ladite composition
EP2970977A4 (fr) Promoteur destiné de préférence aux racines et procédés d'utilisation
EP2964750A4 (fr) Méthodes et compositions utilisables en vue du traitement et/ou de la prévention du diabète de type 1
EP2966991A4 (fr) Promoteur préféré des racines et ses procédés d'utilisation
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201305297D0 (en) Novel agents and uses thereof
GB201520487D0 (en) New game 'Shiki'
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same
UA27219S (uk) Форматор-вулканізатор 75" та 88"
GB201302646D0 (en) Therapeutic uses of flavin-containing monooxygenase 3
TH1401002410B (th) ส่วนลำตัวซึมซับและผลิตภัณฑ์ซึมซับที่ประกอบรวมด้วยส่วนลำตัวซึมซับ
TH1401001876B (th) ลำตัวแบบต่อเนื่องของสายพันข้อมือและสายพันข้อมือ
GB201322203D0 (en) Deens' merger